Relmada Therapeutics, Inc. (RLMD)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $549.62M
- P/E ratio
- —
- EPS
- —
- Volume
- 2,528,035
- 52-week high
- —
- 52-week low
- —
- Open
- $5.28
- Day high
- $5.48
- Day low
- $4.96
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$57.39M | -$1.45 |
| 2024 | — | -$79.98M | -$2.65 |
| 2023 | — | -$98.79M | -$3.28 |
| 2022 | — | -$157.04M | -$5.30 |
| 2021 | — | -$125.75M | -$7.16 |
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
- CEO
- Sergio Traversa
- Employees
- 17
- Country
- US
- IPO date
- Jun 20, 2014
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Relmada Therapeutics, Inc.'s stock price today?
- RLMD is trading at $5.00 as of Jul 20, 2026.
- What is Relmada Therapeutics, Inc.'s market cap?
- Relmada Therapeutics, Inc. (RLMD) has a market capitalization of $549.62M.
- Does Relmada Therapeutics, Inc. pay a dividend?
- Relmada Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Relmada Therapeutics, Inc. in?
- Relmada Therapeutics, Inc. operates in the Healthcare sector.